Deucravacitinib is prescribed for:
- Moderate-to-severe plaque psoriasis
- Adults who are candidates for systemic therapy
- Dermatologic autoimmune conditions
First-in-class selective TYK2 inhibitor.
Back to Medication Guide
Deucravacitinib
Generic Name: Deucravacitinib
Brand Names: Sotyktu
Deucravacitinib is an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.
Dermatologic
What It's Used For
Side Effects
Common side effects:
- Upper respiratory infections
- Increased blood CPK
- Herpes simplex infections
- Acne
- Folliculitis
Serious side effects:
- Serious infections
- Malignancy risk (theoretical)
Additional Information
What is Deucravacitinib?
Deucravacitinib is a first-in-class selective TYK2 inhibitor for psoriasis.
Different from JAK Inhibitors
TYK2 inhibition is more selective than broader JAK inhibition, potentially reducing some safety concerns seen with JAK inhibitors.
Oral Once Daily
Convenient once-daily oral dosing without the titration needed for apremilast.
For details, see MedlinePlus.
Related Health Conditions
This medication is commonly used to treat or manage the following conditions:
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Ask Dr. Zimmer
Have questions about Deucravacitinib? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.